Biogen Company Profile (NASDAQ:BIIB)

About Biogen (NASDAQ:BIIB)

Biogen logoBiogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:BIIB
  • CUSIP: 09062X10
  • Web:
  • Market Cap: $53.2 billion
  • Outstanding Shares: 212,115,000
Average Prices:
  • 50 Day Moving Avg: $265.15
  • 200 Day Moving Avg: $282.38
  • 52 Week Range: $223.02 - $333.65
  • Trailing P/E Ratio: 15.71
  • Foreward P/E Ratio: 11.11
  • P/E Growth: 1.95
Sales & Book Value:
  • Annual Revenue: $11.53 billion
  • Price / Sales: 4.61
  • Book Value: $54.12 per share
  • Price / Book: 4.63
  • EBIDTA: $6.04 billion
  • Net Margins: 32.34%
  • Return on Equity: 38.48%
  • Return on Assets: 20.29%
  • Debt-to-Equity Ratio: 0.54%
  • Current Ratio: 2.55%
  • Quick Ratio: 2.26%
  • Average Volume: 1.56 million shs.
  • Beta: 0.72
  • Short Ratio: 1.52

Frequently Asked Questions for Biogen (NASDAQ:BIIB)

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

How were Biogen's earnings last quarter?

Biogen Inc (NASDAQ:BIIB) announced its quarterly earnings results on Tuesday, April, 25th. The company reported $5.20 EPS for the quarter, beating the consensus estimate of $4.97 by $0.23. The company had revenue of $2.81 billion for the quarter, compared to the consensus estimate of $2.73 billion. Biogen had a return on equity of 38.48% and a net margin of 32.34%. The company's revenue for the quarter was up 3.1% compared to the same quarter last year. During the same quarter last year, the company posted $4.79 earnings per share. View Biogen's Earnings History.

When will Biogen make its next earnings announcement?

Biogen is scheduled to release their next quarterly earnings announcement on Wednesday, July, 19th 2017. View Earnings Estimates for Biogen.

Where is Biogen's stock going? Where will Biogen's stock price be in 2017?

23 analysts have issued 1-year price objectives for Biogen's shares. Their forecasts range from $277.00 to $442.00. On average, they expect Biogen's share price to reach $332.10 in the next twelve months. View Analyst Ratings for Biogen.

What are analysts saying about Biogen stock?

Here are some recent quotes from research analysts about Biogen stock:

  • 1. Cantor Fitzgerald analysts commented, "A German patient treated for three years with Tysabri and then with a single dose of Ocrevus developed PML." (5/25/2017)
  • 2. Cowen and Company analysts commented, "Biogen reported Q1 revenues of $2.81B (+3% Y/Y, vs. consensus of $2.74B) and non-." (4/25/2017)
  • 3. Mizuho analysts commented, "We just started our Spinraza webinar … here’s a link to the slides pdf Rating Neutral Previous Rating No Change Price (4/17) $274.05 Price Target $290.00 Previous Price Target No Change LINK to slides for our Spinraza webinar (for folks who prefer a pdf copy): CLICK HERE Link to join webinar (just started): CLICK HERE We intend to blast a replay of the webinar after we finish. PLEASE REFER TO PAGE 3 OF THIS REPORT FOR IMPORTANT DISCLOSURE AND ANALYST CERTIFICATION INFORMATION. Mizuho Securities USA LLC does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision." (4/18/2017)
  • 4. Instinet analysts commented, "We are initiating on BIIB with a Buy rating and $345 target price. We recommend owning BIIB shares over the next 12 months given limited 2017 downside to revenue forecasts and potential Spinraza launch upside. We estimate that a successful Spinraza launch will drive above-consensus revenues of $11.6bn in 2017 and $12.2bn in 2018, despite flat MS-franchise growth that may be impacted by emerging competition (Ocrevus). We anticipate this return to growth will drive modest revenue multiple expansion and strong GAAP EPS growth - to $19.41 in 2017 and $21.56 in 2018, yielding upside to our $345 target price." (3/1/2017)
  • 5. Jefferies Group LLC analysts commented, "This morning BIIB announced a settlement with FWP around Tecfidera IP. While we believe Street expectations were generally balanced going into the 3/17 decision (and we had assumed 50/50 prob. BIIB would be successful), commercial and some IPR risk remains, and recent focus has been more on Spinraza launch and Alzheimer’s, the terms look reasonable to us and help reduce an overhang." (1/18/2017)

Who are some of Biogen's key competitors?

Who owns Biogen stock?

Biogen's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.34%), Primecap Management Co. CA (7.30%), Vanguard Group Inc. (6.77%), State Street Corp (4.52%), Wellington Management Group LLP (2.69%) and FMR LLC (2.61%). Company insiders that own Biogen stock include Adam Koppel, Adriana Karaboutis, Alexander J Denner, Alfred Sandrock, Caroline Dorsa, Douglas E Williams, George A Scangos, Michel Vounatsos, Paul J Clancy, Robert W Pangia and Stelios Papadopoulos. View Institutional Ownership Trends for Biogen.

Who sold Biogen stock? Who is selling Biogen stock?

Biogen's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Ameriprise Financial Inc., Parametric Portfolio Associates LLC, SG Americas Securities LLC, Korea Investment CORP, William Blair Investment Management LLC, Wellington Management Group LLP and Primecap Management Co. CA. Company insiders that have sold Biogen stock in the last year include Adam Koppel, Adriana Karaboutis, Alfred Sandrock, Caroline Dorsa, George A Scangos, Paul J Clancy and Robert W Pangia. View Insider Buying and Selling for Biogen.

Who bought Biogen stock? Who is buying Biogen stock?

Biogen's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Janus Capital Management LLC, Massachusetts Financial Services Co. MA, Winslow Capital Management LLC, AQR Capital Management LLC, Lazard Asset Management LLC, Westfield Capital Management Co. LP and Vanguard Group Inc.. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner, Michel Vounatsos and Stelios Papadopoulos. View Insider Buying and Selling for Biogen.

How do I buy Biogen stock?

Shares of Biogen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Biogen stock cost?

One share of Biogen stock can currently be purchased for approximately $250.80.

Analyst Ratings

Consensus Ratings for Biogen (NASDAQ:BIIB) (?)
Ratings Breakdown: 11 Hold Ratings, 11 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $332.10 (32.42% upside)

Analysts' Ratings History for Biogen (NASDAQ:BIIB)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/25/2017Sanford C. BernsteinReiterated RatingOutperformLowView Rating Details
5/25/2017Cantor FitzgeraldReiterated RatingHold$277.00LowView Rating Details
5/15/2017Piper Jaffray CompaniesSet Price TargetBuy$332.00 -> $442.00LowView Rating Details
4/27/2017MizuhoReiterated RatingHoldMediumView Rating Details
4/26/2017Stifel NicolausBoost Price TargetHold$265.00 -> $280.00MediumView Rating Details
4/25/2017Cowen and CompanyReiterated RatingBuy$338.00HighView Rating Details
4/23/2017Barclays PLCReiterated RatingOverweight$380.00 -> $360.00MediumView Rating Details
4/18/2017Robert W. BairdReiterated RatingNeutral$290.00LowView Rating Details
4/10/2017Leerink SwannLower Price TargetMarket Perform$300.00 -> $290.00LowView Rating Details
4/4/2017Jefferies Group LLCSet Price TargetHold$289.00LowView Rating Details
4/4/2017Citigroup IncBoost Price TargetBuy$305.00 -> $315.00LowView Rating Details
4/3/2017Credit Suisse Group AGReiterated RatingNeutral$296.00LowView Rating Details
3/16/2017Morgan StanleyDowngradeOverweight -> Equal Weight$369.00 -> $305.00HighView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$223.03 -> $345.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageNeutralN/AView Rating Details
2/2/2017Royal Bank of CanadaReiterated RatingBuyN/AView Rating Details
1/30/2017HC WainwrightReiterated RatingBuy$360.00N/AView Rating Details
1/24/2017BMO Capital MarketsReiterated RatingMarket Perform$336.00N/AView Rating Details
1/18/2017JPMorgan Chase & Co.Reiterated RatingBuyN/AView Rating Details
12/29/2016Raymond James Financial, Inc.Boost Price TargetStrong-Buy$375.00 -> $386.00N/AView Rating Details
9/22/2016Bank of America CorpReiterated RatingBuy$374.00N/AView Rating Details
8/2/2016Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
6/8/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
4/23/2016Goldman Sachs Group IncReiterated RatingHoldN/AView Rating Details
1/27/2016William BlairReiterated RatingOutperformN/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageOverweight$344.00N/AView Rating Details
9/23/2015Oppenheimer Holdings Inc.Reiterated RatingSector PerformN/AView Rating Details
8/11/2015Deutsche Bank AGReiterated RatingBuyN/AView Rating Details
7/27/2015ArgusLower Price TargetBuy$450.00 -> $360.00N/AView Rating Details
6/9/2015GuggenheimInitiated CoverageNeutralN/AView Rating Details
(Data available from 5/26/2015 forward)


Earnings History for Biogen (NASDAQ:BIIB)
Earnings by Quarter for Biogen (NASDAQ:BIIB)
Earnings History by Quarter for Biogen (NASDAQ:BIIB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/25/2017Q1 2017$4.97$5.20$2.73 billion$2.81 billionViewN/AView Earnings Details
1/26/2017Q416$4.96$5.04$2.94 billion$2.87 billionViewN/AView Earnings Details
10/26/2016Q316$4.97$5.19$2.91 billion$2.96 billionViewListenView Earnings Details
7/21/2016Q216$4.69$5.21$2.79 billion$2.89 billionViewListenView Earnings Details
4/21/2016Q116$4.47$4.79$2.75 billion$2.73 billionViewListenView Earnings Details
1/27/2016Q415$4.08$4.50$2.70 billion$2.84 billionViewListenView Earnings Details
10/21/2015Q315$3.80$4.48$2.65 billion$2.39 billionViewListenView Earnings Details
7/24/2015Q215$4.10$4.22$2.71 billion$2.59 billionViewListenView Earnings Details
4/24/2015Q115$3.91$3.82$2.66 billion$2.56 billionViewListenView Earnings Details
1/29/2015Q414$3.74$4.09$2.64 billion$2.60 billionViewListenView Earnings Details
10/22/2014Q3$3.22$3.80$2.48 billion$2.50 billionViewListenView Earnings Details
7/23/2014Q214$2.80$3.49$2.14 billion$2.42 billionViewListenView Earnings Details
4/23/2014Q114$2.56$2.47$2.00 billion$2.10 billionViewListenView Earnings Details
1/29/2014Q413$2.27$2.34$1.93 billion$2.00 billionViewListenView Earnings Details
10/28/2013Q313$2.10$2.35$1.78 billion$1.83 billionViewListenView Earnings Details
7/25/2013Q2 2013$1.93$2.30$1.62 billion$1.70 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.63$1.97$1.41 billion$1.40 billionViewListenView Earnings Details
1/28/2013Q4 2012$1.46$1.40$1.38 billion$1.40 billionViewListenView Earnings Details
10/25/2012$1.60$1.91ViewN/AView Earnings Details
7/24/2012$1.56$1.82ViewN/AView Earnings Details
5/1/2012$1.49$1.40ViewN/AView Earnings Details
1/31/2012$1.49$1.51ViewN/AView Earnings Details
10/28/2011$1.52$1.61ViewN/AView Earnings Details
7/26/2011$1.36$1.36ViewN/AView Earnings Details
4/21/2011$1.41$1.43ViewN/AView Earnings Details
2/1/2011$1.23$1.42ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Biogen (NASDAQ:BIIB)
2017 EPS Consensus Estimate: $19.50
2018 EPS Consensus Estimate: $22.29
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$4.47$5.03$4.75
Q2 20173$3.86$5.01$4.29
Q3 20173$4.94$5.34$5.20
Q4 20174$4.94$5.50$5.26
Q1 20181$5.30$5.30$5.30
Q2 20181$5.52$5.52$5.52
Q3 20181$5.72$5.72$5.72
Q4 20181$5.75$5.75$5.75
(Data provided by Zacks Investment Research)


Dividend History for Biogen (NASDAQ:BIIB)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Biogen (NASDAQ:BIIB)
Insider Ownership Percentage: 0.32%
Institutional Ownership Percentage: 86.97%
Insider Trades by Quarter for Biogen (NASDAQ:BIIB)
Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)
Insider Trades by Quarter for Biogen (NASDAQ:BIIB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/1/2017Michel VounatsosCEOBuy1,402$271.35$380,432.70View SEC Filing  
4/27/2017Alexander J. DennerDirectorBuy73,858$278.50$20,569,453.00View SEC Filing  
4/25/2017Paul J ClancyVPSell9,892$290.00$2,868,680.00View SEC Filing  
4/3/2017Alfred SandrockCMOSell1,981$274.08$542,952.48View SEC Filing  
3/13/2017Paul J ClancyVPSell9,891$291.55$2,883,721.05View SEC Filing  
2/27/2017Michel VounatsosCEOBuy1,333$285.39$380,424.87View SEC Filing  
1/9/2017Robert W PangiaDirectorSell5,450$295.39$1,609,875.50View SEC Filing  
10/4/2016Adriana KaraboutisEVPSell262$311.94$81,728.28View SEC Filing  
10/3/2016Adriana KaraboutisEVPSell380$313.00$118,940.00View SEC Filing  
9/22/2016Caroline DorsaDirectorSell27,570$314.00$8,656,980.00View SEC Filing  
7/21/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
6/6/2016Adam KoppelEVPSell555$290.00$160,950.00View SEC Filing  
6/3/2016George A ScangosCEOSell842$290.00$244,180.00View SEC Filing  
6/1/2016George A ScangosCEOSell3,855$289.74$1,116,947.70View SEC Filing  
5/25/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
5/2/2016George A ScangosCEOSell487$274.74$133,798.38View SEC Filing  
4/6/2016Adam KoppelEVPSell102$275.00$28,050.00View SEC Filing  
4/6/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
4/1/2016George A ScangosCEOSell487$258.83$126,050.21View SEC Filing  
3/1/2016George A ScangosCEOSell487$261.37$127,287.19View SEC Filing  
2/25/2016Adriana KaraboutisEVPSell84$261.90$21,999.60View SEC Filing  
2/25/2016Alfred SandrockCMOSell183$261.90$47,927.70View SEC Filing  
2/17/2016Alfred SandrockChief Medical OfficerSell722$256.16$184,947.52View SEC Filing  
2/17/2016George A ScangosCEOSell487$256.16$124,749.92View SEC Filing  
2/9/2016Alfred SandrockChief Medical OfficerSell852$246.54$210,052.08View SEC Filing  
12/4/2015Alfred SandrockCMOSell441$277.00$122,157.00View SEC Filing  
10/23/2015Alexander J DennerDirectorBuy310,000$277.47$86,015,700.00View SEC Filing  
7/27/2015Stelios PapadopoulosDirectorBuy10,000$304.88$3,048,800.00View SEC Filing  
6/19/2015Douglas E WilliamsEVPSell3,841$410.00$1,574,810.00View SEC Filing  
6/1/2015George A ScangosCEOSell1,362$398.87$543,260.94View SEC Filing  
4/1/2015George A ScangosCEOSell1,362$423.20$576,398.40View SEC Filing  
3/25/2015John CoxEVPSell12,010$449.06$5,393,210.60View SEC Filing  
3/20/2015Eric K RowinskyDirectorSell11,667$475.00$5,541,825.00View SEC Filing  
3/19/2015Eric K RowinskyDirectorSell2,333$436.14$1,017,514.62View SEC Filing  
3/17/2015Eric K RowinskyDirectorSell4,667$425.45$1,985,575.15View SEC Filing  
3/10/2015Robert W PangiaDirectorSell3,625$413.40$1,498,575.00View SEC Filing  
3/2/2015Alfred SandrockSVPSell3,174$409.49$1,299,721.26View SEC Filing  
2/17/2015Steven H HoltzmanEVPSell2,128$389.11$828,026.08View SEC Filing  
2/10/2015Alfred SandrockSVPSell1,143$398.11$455,039.73View SEC Filing  
2/2/2015Kenneth DipietroEVPSell1,656$389.03$644,233.68View SEC Filing  
12/15/2014Spyridon Artavanis-TsakonasSVPSell1,981$346.50$686,416.50View SEC Filing  
12/2/2014Steven H HoltzmanEVPSell1,749$335.65$587,051.85View SEC Filing  
11/11/2014Steven H HoltzmanEVPSell1,750$330.00$577,500.00View SEC Filing  
11/3/2014George A ScangosCEOSell1,128$320.78$361,839.84View SEC Filing  
10/1/2014George A ScangosCEOSell1,127$330.97$373,003.19View SEC Filing  
10/1/2014Steven H HoltzmanEVPSell1,750$330.97$579,197.50View SEC Filing  
8/1/2014George A ScangosCEOSell1,128$332.93$375,545.04View SEC Filing  
7/16/2014George A ScangosCEOSell12,316$312.37$3,847,148.92View SEC Filing  
5/19/2014Steven HoltzmanEVPSell1,221$289.15$353,052.15View SEC Filing  
5/1/2014George ScangosCEOSell2,123$285.56$606,243.88View SEC Filing  
4/17/2014Steven HoltzmanEVPSell1,221$291.00$355,311.00View SEC Filing  
4/1/2014George ScangosCEOSell2,123$308.42$654,775.66View SEC Filing  
4/1/2014Robert PangiaDirectorSell6,250$308.42$1,927,625.00View SEC Filing  
3/31/2014Brian PosnerDirectorSell3,000$296.76$890,280.00View SEC Filing  
3/20/2014Caroline DorsaDirectorSell10,000$348.88$3,488,800.00View SEC Filing  
3/19/2014Douglas WilliamsEVPSell3,505$352.29$1,234,776.45View SEC Filing  
3/17/2014Steven HoltzmanEVPSell1,221$334.83$408,827.43View SEC Filing  
3/11/2014Stuart KingsleyEVPSell8,428$336.83$2,838,803.24View SEC Filing  
3/3/2014George ScangosCEOSell2,942$335.79$987,894.18View SEC Filing  
2/26/2014Alfred SandrockSVPSell1,048$342.17$358,594.16View SEC Filing  
2/18/2014Steven HoltzmanEVPSell1,222$327.90$400,693.80View SEC Filing  
2/13/2014Kenneth DipietroEVPSell1,290$316.81$408,684.90View SEC Filing  
2/11/2014Alfred SandrockSVPSell2,085$314.31$655,336.35View SEC Filing  
2/11/2014George ScangosCEOSell2,456$314.31$771,945.36View SEC Filing  
2/4/2014Kenneth DipietroEVPSell1,655$299.01$494,861.55View SEC Filing  
1/21/2014Eric RowinskyDirectorSell2,020$310.09$626,381.80View SEC Filing  
1/15/2014Lynn SchenkDirectorSell1,000$297.48$297,480.00View SEC Filing  
1/8/2014William YoungDirectorSell15,000$285.11$4,276,650.00View SEC Filing  
1/6/2014Robert PangiaDirectorSell6,250$278.03$1,737,687.50View SEC Filing  
12/2/2013Lynn SchenkDirectorSell1,000$291.71$291,710.00View SEC Filing  
11/22/2013Raymond PawlickiSVPSell4,000$288.00$1,152,000.00View SEC Filing  
11/1/2013George A ScangosCEOSell2,239$245.57$549,831.23View SEC Filing  
11/1/2013Lynn SchenkDirectorSell1,000$245.00$245,000.00View SEC Filing  
10/22/2013Alfred SandrockSVPSell15,030$250.11$3,759,153.30View SEC Filing  
9/18/2013Paul ClancyCFOSell26,785$245.00$6,562,325.00View SEC Filing  
9/17/2013Steven HoltzmanEVPSell3,501$238.98$836,668.98View SEC Filing  
9/16/2013Paul ClancyCFOSell99,030$238.27$23,595,878.10View SEC Filing  
9/16/2013Raymond PawlickiSVPSell4,000$238.03$952,120.00View SEC Filing  
9/3/2013George ScangosCEOSell2,239$214.40$480,041.60View SEC Filing  
8/26/2013Douglas WilliamsEVPSell4,368$211.35$923,176.80View SEC Filing  
8/1/2013George A ScangosCEOSell2,239$218.82$489,937.98View SEC Filing  
7/16/2013George A ScangosCEOSell2,239$223.94$501,401.66View SEC Filing  
6/14/2013Alexander J DennerDirectorSell2,900$212.00$614,800.00View SEC Filing  
6/11/2013Brian S PosnerDirectorSell2,020$219.62$443,632.40View SEC Filing  
6/10/2013Lynn SchenkDirectorSell2,000$225.82$451,640.00View SEC Filing  
6/3/2013George A ScangosCEOSell1,598$234.16$374,187.68View SEC Filing  
6/3/2013Stephen A SherwinDirectorSell12,825$233.26$2,991,559.50View SEC Filing  
5/28/2013Robert W PangiaDirectorSell5,900$237.23$1,399,657.00View SEC Filing  
12/27/2012Alexander J DennerDirectorSell7,980$148.62$1,185,987.60View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Biogen (NASDAQ:BIIB)
Latest Headlines for Biogen (NASDAQ:BIIB)
DateHeadline logoDeadly brain infection in German MS patient prompts Roche investigation - May 24 at 8:51 PM logoNotable Wednesday Option Activity: JNJ, C, BIIB - May 24 at 3:50 PM logoBiogen (BIIB) FAMPYRA Receives EU Approval for Standard Marketing Authorization for Improvement of Walking in People with MS - May 24 at 12:41 PM logoBiogen Inc (BIIB) Receives Average Rating of "Buy" from Brokerages - May 23 at 2:21 PM logoBiogen to Present at the Bernstein 33rd Annual Strategic Decisions Conference - May 17 at 8:58 PM logoBiogen (BIIB) Buys Stroke Candidate Cirara for $120M - May 16 at 4:00 PM logoBiogen nabs stroke treatment for $120M, eyeing late-stage trial - May 15 at 4:04 PM logoBiogen Inc (BIIB) PT Set at $442.00 by Piper Jaffray Companies - May 15 at 3:14 PM logo3 Things In Biotech You Should Learn Today: May 14, 2017 - May 14 at 9:59 AM logoBiogen Enters Oversold Territory (BIIB) - Nasdaq - May 11 at 4:29 PM logoCantor Fitzgerald Weighs in on Biogen Inc's FY2017 Earnings (BIIB) - May 11 at 11:30 AM logoIYH's Underlying Holdings Could Mean 10% Gain Potential - May 9 at 3:55 PM logoHuge Hedge Fund, Biotech and Technology Trades Highlight Insider Buying: Apollo Global, Biogen, Twitter, DDR and ... - 24/7 Wall St. - May 7 at 4:08 PM logoWhy Biogen Inc. Shareholders Have Something to Worry About - May 7 at 11:43 AM logoNotable Friday Option Activity: BIIB, NWL, NKE - May 5 at 3:56 PM logo[$$] Big Sales by Biogen CFO Don't Deter Buying - May 5 at 3:55 PM logoSomewhat Positive Media Coverage Likely to Impact Biogen (BIIB) Share Price - May 4 at 4:26 PM logoWhat's Behind Ionis Pharmaceuticals' 20% Rally In April - May 4 at 10:14 AM logoVetr Inc. Lowers Biogen Inc (BIIB) to Buy - May 3 at 1:09 AM logoBiogen Inc (BIIB) CEO Purchases $380,432.70 in Stock - May 2 at 9:50 PM logoBiogen Inc (BIIB) Director Purchases $20,569,453.00 in Stock - May 1 at 9:38 PM logoFeuerstein On Neurotrope: The Study Failed And There Was Never 'A Lot Of Hope Here' - Benzinga - May 1 at 3:54 PM logoSomewhat Positive Press Coverage Likely to Impact Biogen (BIIB) Stock Price - May 1 at 12:45 PM logoBiogen Inc (BIIB) Given New $280.00 Price Target at Stifel Nicolaus - May 1 at 12:14 AM logo$2.79 Billion in Sales Expected for Biogen Inc (BIIB) This Quarter - April 29 at 10:14 AM logoBiogen (BIIB) Receiving Somewhat Favorable News Coverage, Study Finds - April 28 at 10:08 PM logoBiogen Inc (BIIB) Upgraded by Vetr Inc. to "Strong-Buy" - April 28 at 8:04 PM logoBiogen Inc (BIIB) Given Average Recommendation of "Buy" by Brokerages - April 28 at 4:39 PM logoBiogen Inc (BIIB) to Post Q2 2017 Earnings of $3.86 Per Share, Leerink Swann Forecasts - April 28 at 11:14 AM logoVetr Inc. Upgrades Biogen Inc (BIIB) to Strong-Buy - April 28 at 1:05 AM logoBiogen Inc (BIIB) Receives "Hold" Rating from Mizuho - April 27 at 10:44 PM logoBiogen Inc (BIIB) VP Sells $2,868,680.00 in Stock - April 27 at 9:04 PM logoBiogen Inc. Earnings: New Drug Sparks Life - Motley Fool - April 27 at 8:32 PM logoBiogen's Spinraza Dazzles But Rivals Rally - Seeking Alpha - April 27 at 3:29 PM logoBiogen Reports Strong Revenue Growth in 1Q17 - April 27 at 3:29 PM logoAnalysts’ Recommendations for Biogen in 1Q17 - April 27 at 3:29 PM logoBiogen Still Dominated the Multiple Sclerosis Market in 1Q17 - April 27 at 3:29 PM logoBiogen, Inc. :BIIB-US: Earnings Analysis: Q1, 2017 By the Numbers : April 27, 2017 - April 27 at 3:29 PM logoLeerink Swann Comments on Biogen Inc's FY2017 Earnings (BIIB) - April 27 at 2:01 PM logoBrokers Issue Forecasts for Biogen Inc's Q2 2017 Earnings (BIIB) - April 27 at 9:52 AM logo$5.18 Earnings Per Share Expected for Biogen Inc (BIIB) This Quarter - April 27 at 8:46 AM
News IconA biotech's new drug sold 3 times better than expected - and the stock is taking off - Business Insider - April 27 at 1:23 AM logoBiogen Inc (BIIB) Stock Pops on Strong Q1 Earnings - - April 27 at 1:23 AM logoBiogen Inc. Earnings: New Drug Sparks Life - April 26 at 4:00 PM logoBiogen Inc. Q1 Earnings Climb 7% - Nasdaq - April 26 at 3:22 PM logoBiogen: Key Q1 2017 Insights - Seeking Alpha - April 26 at 3:22 PM logo​Hyde Park boy with rare disease wins appeal, will receive Biogen drug - April 26 at 3:21 PM logoBiogen Earnings Top As $125,000 Drug Starts Well - April 26 at 12:40 PM logoSpinraza's Fast Start Puts Ionis on a Path to Profit - April 26 at 12:40 PM logoToday's Research Reports on Stocks to Watch: Lockheed Martin and Biogen - April 26 at 12:40 PM



Biogen (BIIB) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by Staff